Oragenics Inc
OGEN
$1.09
Closing
▲2.83%
1D
▼-80.63%
YTD
Market cap
$4.88M
52 week high
$7.65
52 week low
$1.02
Volume
1,409
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$4.88M
Analysts' Rating
-
Price Target (Mean)
-
Total Analysts
0
P/E
Operating Margin
-28038.02%
Beta
0.39
Revenue Growth (Annual)
51.20%
52 week high
$7.65
52 week low
$1.02
Div. Yield
%
EPS Annual Growth
-43.30
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. The Company’s lead product NT-CoV2-1 is an intranasal vaccine candidate to prevent coronavirus disease (COVID-19) from the SARS-CoV-2 virus and variants thereof. Its lantibiotics program features a novel class of antibiotics against bacteria its research has shown may be applicable to multiple antibiotic-resistant organisms. Its Antibiotics product is a semi-synthetic analog of MU1140, which is a member of lantibiotic class of antibiotics. Through its wholly owned subsidiary, Noachis Terra, is engaged in the research and development stage for its new Terra CoV-2 and NT-CoV2-1 vaccine product candidates. It is also developing semi-synthetic lantibiotic analogs that may be effective against systemic Gram-positive multidrug infections, and analogs that may be effective in treating Gram-negative infections.
